These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38402895)

  • 1. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Noor NM; Lee JC; Bond S; Dowling F; Brezina B; Patel KV; Ahmad T; Banim PJ; Berrill JW; Cooney R; De La Revilla Negro J; de Silva S; Din S; Durai D; Gordon JN; Irving PM; Johnson M; Kent AJ; Kok KB; Moran GW; Mowat C; Patel P; Probert CS; Raine T; Saich R; Seward A; Sharpstone D; Smith MA; Subramanian S; Upponi SS; Wiles A; Williams HRT; van den Brink GR; Vermeire S; Jairath V; D'Haens GR; McKinney EF; Lyons PA; Lindsay JO; Kennedy NA; Smith KGC; Parkes M;
    Lancet Gastroenterol Hepatol; 2024 May; 9(5):415-427. PubMed ID: 38402895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
    Yanai H; Levine A; Hirsch A; Boneh RS; Kopylov U; Eran HB; Cohen NA; Ron Y; Goren I; Leibovitzh H; Wardi J; Zittan E; Ziv-Baran T; Abramas L; Fliss-Isakov N; Raykhel B; Gik TP; Dotan I; Maharshak N
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):49-59. PubMed ID: 34739863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
    Boyapati RK; Torres J; Palmela C; Parker CE; Silverberg OM; Upadhyaya SD; Nguyen TM; Colombel JF
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012540. PubMed ID: 29756637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial.
    Parkes M; Noor NM; Dowling F; Leung H; Bond S; Whitehead L; Upponi S; Kinnon P; Sandham AP; Lyons PA; McKinney EF; Smith KGC; Lee JC
    BMJ Open; 2018 Dec; 8(12):e026767. PubMed ID: 30523133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    van Linschoten RCA; Jansen FM; Pauwels RWM; Smits LJT; Atsma F; Kievit W; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; van der Woude CJ; Hoentjen F;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):343-355. PubMed ID: 36736339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
    Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
    Khanna R; Bressler B; Levesque BG; Zou G; Stitt LW; Greenberg GR; Panaccione R; Bitton A; Paré P; Vermeire S; D'Haens G; MacIntosh D; Sandborn WJ; Donner A; Vandervoort MK; Morris JC; Feagan BG;
    Lancet; 2015 Nov; 386(10006):1825-34. PubMed ID: 26342731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
    Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
    World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Townsend CM; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Wang Y; Tsoulis DJ; MacDonald JK; Feagan BG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD003459. PubMed ID: 25099640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
    Chande N; Patton PH; Tsoulis DJ; Thomas BS; MacDonald JK
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD000067. PubMed ID: 26517527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.
    Hoekman DR; Stibbe JA; Baert FJ; Caenepeel P; Vergauwe P; De Vos M; Hommes DW; Benninga MA; Vermeire SA; D'Haens GR;
    J Crohns Colitis; 2018 Apr; 12(5):517-524. PubMed ID: 29401297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.
    Edwards SJ; Barton S; Bacelar M; Karner C; Cain P; Wakefield V; Marceniuk G
    Health Technol Assess; 2021 Mar; 25(23):1-138. PubMed ID: 33783345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Tsoulis DJ; MacDonald JK
    Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
    Schulberg JD; Wright EK; Holt BA; Hamilton AL; Sutherland TR; Ross AL; Vogrin S; Miller AM; Connell WC; Lust M; Ding NS; Moore GT; Bell SJ; Shelton E; Christensen B; De Cruz P; Rong YJ; Kamm MA
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):318-331. PubMed ID: 34890567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
    Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.